Apyx Medical (APYX) Stock Price

Apyx Medical Price

NASDAQ·CLOSED
3.03USD-0.0100 (-0.33 %)
Market closed

Over the last 19 years Apyx Medical grew revenue by 3.7% annually, reaching 52.84 M USD. Earnings per share have grown at 23.5% per year over the last 12 years. For Apyx Medical, the net margin of -21.2% is up versus -31.3% a few years ago. The consensus 12-month price target for Apyx Medical is 5.61 USD, about 85.1% above where the stock trades today. Of 11 analysts, 9 rate the stock a buy — an overall Buy consensus. The stock trades about 59% above its 52-week low.

Apyx Medical stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Apyx Medical over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Apyx Medical stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Apyx Medical's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Apyx Medical Stock Price History
DateApyx Medical Price
8/14/20263.03 USD
8/13/20263.04 USD
8/12/20262.97 USD
8/10/20263.46 USD
8/7/20264.05 USD
8/6/20264.16 USD
8/5/20264.14 USD
8/4/20264.30 USD
8/3/20264.18 USD
7/31/20264.10 USD
7/30/20264.12 USD
7/29/20263.70 USD
7/27/20263.86 USD
7/23/20263.83 USD
7/22/20263.91 USD
7/21/20264.12 USD
7/20/20264.07 USD
7/17/20264.28 USD
7/16/20264.34 USD
7/15/20264.42 USD
7/14/20264.22 USD
7/13/20264.24 USD
7/10/20264.38 USD
7/9/20264.46 USD
7/8/20264.14 USD
7/7/20264.20 USD
7/6/20264.45 USD
7/2/20264.30 USD
7/1/20264.66 USD
6/30/20264.49 USD
6/29/20264.69 USD
6/26/20264.50 USD
6/25/20264.17 USD
6/24/20264.12 USD
6/23/20264.08 USD
6/22/20263.97 USD
6/18/20264.11 USD
6/17/20264.21 USD
6/16/20264.15 USD
6/15/20264.60 USD
6/12/20264.69 USD
6/11/20264.65 USD
6/10/20264.91 USD
6/9/20264.86 USD
6/8/20264.77 USD
6/5/20264.47 USD
6/4/20264.29 USD
6/3/20263.79 USD
6/2/20263.85 USD
6/1/20263.96 USD
5/29/20263.99 USD
5/28/20264.15 USD
5/27/20263.90 USD
5/26/20264.09 USD
5/22/20264.13 USD
5/21/20264.25 USD
5/20/20263.79 USD
5/19/20263.94 USD
5/18/20263.87 USD
5/15/20264.05 USD
5/14/20264.36 USD
5/13/20263.84 USD
5/12/20264.09 USD
5/11/20263.92 USD
5/8/20263.67 USD
5/7/20263.56 USD
5/6/20262.92 USD
5/5/20262.79 USD
5/4/20262.85 USD
5/1/20263.06 USD
4/30/20263.33 USD
4/29/20263.46 USD
4/28/20263.67 USD
4/27/20263.76 USD
4/24/20263.72 USD
4/23/20263.82 USD
4/22/20263.83 USD
4/21/20263.90 USD
4/20/20263.94 USD
4/17/20263.98 USD
4/16/20263.94 USD
4/15/20263.90 USD
4/14/20263.84 USD
4/13/20263.88 USD
4/10/20263.96 USD
4/9/20264.00 USD
4/8/20263.81 USD
4/7/20263.75 USD
4/6/20263.76 USD
4/2/20263.68 USD
4/1/20263.63 USD
3/31/20263.69 USD
3/30/20263.58 USD
3/27/20263.64 USD
3/26/20263.84 USD
3/25/20263.89 USD
3/24/20263.94 USD
3/23/20263.98 USD
3/20/20263.48 USD
3/19/20263.53 USD
3/18/20263.67 USD
3/17/20263.74 USD
3/16/20263.67 USD
3/13/20263.63 USD
3/12/20263.62 USD
3/11/20263.93 USD
3/10/20263.45 USD
3/9/20263.43 USD
3/6/20263.12 USD
3/5/20263.26 USD
3/4/20263.30 USD
3/3/20263.17 USD
3/2/20263.28 USD
2/27/20263.27 USD
2/26/20263.50 USD
2/25/20263.42 USD
2/24/20263.54 USD
2/23/20263.57 USD
2/20/20263.78 USD
2/19/20263.75 USD
2/18/20263.92 USD
2/17/20263.84 USD
2/13/20263.72 USD
2/12/20263.82 USD
2/11/20263.92 USD
2/10/20263.98 USD
2/9/20264.08 USD
2/6/20263.88 USD
2/5/20263.94 USD
2/4/20263.97 USD
2/3/20264.39 USD
2/2/20264.40 USD
1/30/20264.02 USD
1/29/20264.05 USD
1/28/20264.01 USD
1/27/20264.19 USD
1/26/20263.87 USD
1/23/20263.97 USD
1/22/20263.95 USD
1/21/20263.99 USD
1/20/20263.85 USD
1/16/20263.99 USD
1/15/20263.89 USD
1/14/20263.76 USD
1/13/20263.88 USD
1/12/20264.01 USD
1/9/20263.49 USD
1/8/20263.46 USD
1/7/20263.46 USD
1/6/20263.56 USD
1/5/20263.54 USD
1/2/20263.50 USD
12/31/20253.50 USD
12/30/20253.44 USD
12/29/20253.50 USD
12/26/20253.44 USD
12/24/20253.60 USD
12/23/20253.60 USD
12/22/20253.61 USD
12/19/20253.49 USD
12/18/20253.71 USD
12/17/20253.65 USD
12/16/20253.72 USD
12/15/20253.79 USD
12/12/20253.86 USD
12/11/20253.99 USD
12/10/20254.03 USD
12/9/20254.07 USD
12/8/20253.96 USD
12/5/20253.94 USD
12/4/20254.03 USD
12/3/20254.00 USD
12/2/20254.07 USD
12/1/20254.02 USD
11/28/20254.01 USD
11/26/20254.01 USD
11/25/20254.00 USD
11/24/20253.87 USD
11/21/20254.00 USD
11/20/20254.04 USD
11/19/20253.95 USD
11/18/20253.81 USD
11/17/20254.03 USD
11/14/20253.90 USD
11/13/20254.07 USD
11/12/20254.33 USD
11/11/20254.00 USD
11/10/20254.10 USD
11/7/20253.87 USD
11/6/20253.35 USD
11/5/20253.14 USD
11/4/20253.24 USD
11/3/20253.20 USD
10/31/20253.03 USD
10/30/20252.95 USD
10/29/20252.95 USD
10/28/20253.10 USD
10/27/20253.13 USD
10/24/20253.21 USD
10/23/20252.90 USD
10/22/20253.03 USD
10/21/20253.08 USD
10/20/20253.13 USD
10/17/20252.92 USD
10/16/20253.11 USD
10/15/20253.11 USD
10/14/20253.40 USD
10/13/20253.00 USD
10/10/20252.97 USD
10/9/20252.99 USD
10/8/20252.87 USD
10/7/20252.84 USD
10/6/20252.89 USD
10/3/20252.39 USD
10/2/20252.09 USD
10/1/20252.15 USD
9/30/20252.14 USD
9/29/20252.18 USD
9/26/20252.02 USD
9/25/20252.05 USD
9/24/20252.05 USD
9/23/20252.09 USD
9/22/20252.02 USD
9/19/20252.29 USD
9/18/20252.24 USD
9/17/20252.20 USD
9/16/20252.13 USD
9/15/20252.13 USD
9/12/20252.10 USD
9/11/20252.00 USD
9/10/20251.97 USD
9/9/20252.06 USD
9/8/20252.06 USD
9/5/20251.96 USD
9/4/20252.05 USD
9/3/20251.90 USD
9/2/20251.92 USD
8/29/20251.99 USD
8/28/20252.02 USD
8/27/20251.98 USD
8/26/20252.08 USD
8/25/20252.06 USD
8/22/20252.09 USD
8/21/20252.06 USD
8/20/20252.03 USD
8/19/20251.97 USD
8/18/20252.14 USD
Access this data via the Eulerpool API
Get Free API Key

Apyx Medical Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
48.52 M USD
-14.45 M USD
-15.17 M USD
Jan 1, 2022
44.51 M USD
-23.56 M USD
-23.18 M USD
Jan 1, 2023
52.35 M USD
-20.46 M USD
-18.71 M USD
Jan 1, 2024
48.10 M USD
-19.01 M USD
-23.46 M USD
Jan 1, 2025
52.84 M USD
-6.45 M USD
-11.21 M USD
Jan 1, 2026 (e)
59.55 M USD
-19.53 M USD
-9.53 M USD
Jan 1, 2027 (e)
66.12 M USD
-21.68 M USD
-8.89 M USD
Jan 1, 2028 (e)
76.40 M USD
-25.06 M USD
-3.91 M USD

Apyx Medical Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 17, 2026, 8:51 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20132014201520162017201820192020202120222023202420252026e2027e2028e
23.0027.0029.0036.0038.0016.0028.0027.0048.0044.0052.0048.0052.0059.0066.0076.00
-14.8117.397.4124.145.56-57.8975.00-3.5777.78-8.3318.18-7.698.3313.4611.8615.15
39.1329.6341.3847.2250.0062.5067.8662.9668.7565.9163.4660.4236.5436.5436.5436.54
9.008.0012.0017.0019.0010.0019.0017.0033.0029.0033.0029.0019.0021.5624.1227.77
-3.00-5.00-6.00-3.00-5.00-13.00-20.00-20.00-14.00-23.00-20.00-19.00-6.00-19.00-21.00-25.00
-13.04-18.52-20.69-8.33-13.16-81.25-71.43-74.07-29.17-52.27-38.46-39.58-11.54-32.20-31.82-32.89
-4.00-17.00-5.00-3.00-5.0064.00-19.00-11.00-15.00-23.00-18.00-23.00-11.00-9.00-8.00-3.00
–325.00-70.59-40.0066.67-1,380.00-129.69-42.1136.3653.33-21.7427.78-52.17-18.18-11.11-62.50
17.6820.3727.0528.6232.8633.6934.1634.2734.3734.6034.6438.2242.1642.1642.1642.16
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Apyx Medical generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Apyx Medical retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Apyx Medical's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Apyx Medical has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Apyx Medical's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Apyx Medical stock margins

The Apyx Medical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Apyx Medical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Apyx Medical.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
69.26 %
-29.78 %
-31.27 %
Jan 1, 2022
65.45 %
-52.94 %
-52.09 %
Jan 1, 2023
64.49 %
-39.08 %
-35.75 %
Jan 1, 2024
61.04 %
-39.51 %
-48.78 %
Jan 1, 2025
36.02 %
-12.20 %
-21.22 %
Jan 1, 2026 (e)
36.02 %
-32.80 %
-15.99 %
Jan 1, 2027 (e)
36.02 %
-32.80 %
-13.44 %
Jan 1, 2028 (e)
36.02 %
-32.80 %
-5.12 %

Apyx Medical Stock Revenue, EBIT, Earnings per Share

The Apyx Medical earnings per share therefore indicates how much revenue Apyx Medical has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
1.41 USD
-0.42 USD
-0.44 USD
Jan 1, 2022
1.29 USD
-0.68 USD
-0.67 USD
Jan 1, 2023
1.51 USD
-0.59 USD
-0.54 USD
Jan 1, 2024
1.26 USD
-0.50 USD
-0.61 USD
Jan 1, 2025
1.25 USD
-0.15 USD
-0.27 USD
Jan 1, 2026 (e)
1.68 USD
-0.46 USD
-0.27 USD
Jan 1, 2027 (e)
1.86 USD
-0.51 USD
-0.25 USD
Jan 1, 2028 (e)
2.15 USD
-0.59 USD
-0.11 USD

Apyx Medical business model & stock analysis

Apyx Medical Corp is a US-American company specializing in the development and manufacturing of medical devices for medical aesthetics. The company is headquartered in Clearwater, Florida and has been listed on the Nasdaq stock exchange since 1997. However, the company was founded much earlier, in 1986, under the name Bovie Medical Corporation. Apyx Medical Corp's business model is focused on helping doctors and other medical professionals achieve better results for their patients. The company offers a wide range of medical aesthetic devices, which are divided into two main categories: devices for electrosurgery and devices for laser surgery. Electrosurgical devices use high frequencies to cut and coagulate tissue. These devices are primarily used for the removal of skin lesions, skin tightening, and the removal of wrinkles and excess tissue. Laser surgical devices, on the other hand, use laser beams to treat various skin problems, including the removal of wrinkles, pigmentation spots, and scars. Over the years, Apyx Medical Corp has become one of the leading companies in the field of medical aesthetics. The company is able to offer its customers a wide range of high-quality products that meet the highest standards of quality. The products of Apyx Medical Corp are used by medical professionals all over the world. The company also has a strong presence in the field of training and education for medical professionals. Apyx Medical Corp offers training and courses to ensure that doctors and other medical professionals can learn and apply the latest techniques and procedures in medical aesthetics. Apyx Medical Corp's products also include the J-Plasma and Renuvion systems. The Renuvion system is an advancement of the J-Plasma system and uses a high-frequency plasma arc to cut and coagulate tissue. The Renuvion system has a wide range of applications, ranging from fat removal to skin tightening. In recent years, Apyx Medical Corp has received a number of awards and recognitions. In 2019, the company was named one of America's best small companies by Forbes magazine. The company has also been included in Inc. Magazine's list of the 5000 fastest-growing companies. In the future, Apyx Medical Corp plans to further expand its product portfolio and strengthen its presence in the global market. The company is committed to providing its customers with the best products, training, and education in medical aesthetics and to remain a leading company in this field. In conclusion, Apyx Medical Corp is a leading company in the field of medical aesthetics, specializing in the development and manufacturing of medical devices. The company offers a wide range of high-quality products and training, and has become one of America's best small companies in recent years. Apyx Medical Corp has a promising future and is committed to providing its customers with the best products and services in the global market.

Apyx Medical SWOT Analysis

Strengths

Apyx Medical Corp has several strengths that contribute to its success in the medical technology industry.

  • Strong product portfolio with innovative medical devices.
  • Advanced technology and research capabilities.
  • Established brand reputation and recognition.
  • Strong distribution network and strategic partnerships.
  • Experienced and skilled workforce.

Weaknesses

Despite its strengths, Apyx Medical Corp also faces certain weaknesses that need to be addressed.

  • Relatively high production costs affecting profit margins.
  • Dependence on a limited number of key customers.
  • Limited geographical presence in certain markets.
  • Intense competition from larger and well-established competitors.
  • Regulatory challenges and compliance issues.

Opportunities

Apyx Medical Corp can leverage various opportunities to further expand its market presence and profitability.

  • Growing global demand for minimally invasive medical devices.
  • Emerging markets offering potential for market expansion.
  • Increasing adoption of advanced surgical techniques.
  • Potential partnerships and collaborations with healthcare providers.
  • Technological advancements to enhance existing product offerings.

Threats

Apyx Medical Corp should also be aware of potential threats that could impact its operations and market position.

  • Changing regulatory environment and increased scrutiny.
  • Economic downturns affecting healthcare spending.
  • Threat of new entrants and disruptive technologies in the market.
  • Potential product recalls or safety concerns.
  • Risk of intellectual property infringement.

Apyx Medical Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Apyx Medical Employees
Details
Date
Apyx Medical Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Apyx Medical Segments

Apyx Medical Revenue by Segment (1/2)

  • 3 Years

  • 5 Years

  • Max

Electrosurgical
Cauteries
Other
Lighting
Details
Date
Electrosurgical
Cauteries
Other
Lighting
Jan 1, 2016
20.90 M USD
7.10 M USD
8.63 M USD
0.00 USD
Jan 1, 2017
25.73 M USD
7.14 M USD
3.58 M USD
2.44 M USD
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Apyx Medical Revenue by Segment (2/2)

  • 3 Years

  • 5 Years

  • Max

Core
Advanced Energy
OEM
J-Plasma
Details
Date
Core
Advanced Energy
OEM
J-Plasma
Jan 1, 2016
27.81 M USD
0.00 USD
5.33 M USD
3.49 M USD
Jan 1, 2017
28.65 M USD
7.64 M USD
2.60 M USD
0.00 USD
Jan 1, 2018
0.00 USD
13.07 M USD
3.62 M USD
0.00 USD

Apyx Medical Revenue by Region

  • 3 Years

  • 5 Years

  • Max

United States
Domestic
Other Countries
International
Details
Date
United States
Domestic
Other Countries
International
Jan 1, 2017
0.00 USD
33.15 M USD
0.00 USD
5.74 M USD
Jan 1, 2018
0.00 USD
12.86 M USD
0.00 USD
3,828.00 USD
Jan 1, 2019
0.00 USD
19.58 M USD
0.00 USD
8.65 M USD
Jan 1, 2020
0.00 USD
18.81 M USD
0.00 USD
8.90 M USD
Jan 1, 2021
0.00 USD
32.98 M USD
0.00 USD
15.54 M USD
Jan 1, 2023
0.00 USD
38.35 M USD
0.00 USD
14.00 M USD
Jan 1, 2024
34.02 M USD
0.00 USD
14.08 M USD
0.00 USD
Jan 1, 2025
38.80 M USD
0.00 USD
14.04 M USD
0.00 USD

Apyx Medical Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Apyx Medical historical P/E ratio, EBIT multiple, and P/S ratio

Apyx Medical annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Apyx Medical shares outstanding

The number of shares of Apyx Medical was 42.16 M in 2025. This indicates how many shares Apyx Medical is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
34.37 M Stocks
Jan 1, 2022
34.60 M Stocks
Jan 1, 2023
34.64 M Stocks
Jan 1, 2024
38.22 M Stocks
Jan 1, 2025
42.16 M Stocks
Jan 1, 2026 (e)
42.16 M Stocks
Jan 1, 2027 (e)
42.16 M Stocks
Jan 1, 2028 (e)
42.16 M Stocks

Current Apyx Medical forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
81.82 % (9)
Hold
18.18 % (2)
Sell
0.00 % (0)
12M Price Target
5.61
Last Price
3.03
Currency
USD
12M Return Potential
85.15 %
LTM Return
0 %

Apyx Medical Analyst Rating Actions

DateFirmActionRatingReliability
3/11/2026
Craig-Hallum
Craig-Hallum
MaintainedBuy–
3/11/2026
BTIG
BTIG
UpgradeNeutralBuy–
11/12/2025
Citizens
Citizens
UpgradeMarket PerformMarket Outperform–
11/10/2023
Stephens & Co.
Stephens & Co.
MaintainedOverweight–
8/11/2023
Piper Sandler
Piper Sandler
MaintainedOverweight51
6/15/2023
Lake Street
Lake Street
MaintainedBuy–
5/24/2023
JMP Securities
JMP Securities
MaintainedMarket PerformPerform–
5/12/2023
Lake Street
Lake Street
MaintainedBuy–
8/12/2022
Piper Sandler
Piper Sandler
MaintainedOverweight51
7/19/2022
Lake Street
Lake Street
MaintainedBuy–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Apyx Medical Earnings Calls

2025

Apyx Medical Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/6/2026-0.08USD-13.44 MUSD-2026 Q2
5/7/2026-0.11USD-11.09 MUSD-2026 Q1
3/12/2026-0.06USD-18.24 MUSD-2025 Q4
11/7/2024-0.19USD-12.01 MUSD-2024 Q3
5/9/2024-0.14USD-14.00 MUSD-2024 Q1
3/14/2024-0.17USD-15.89 MUSD-2023 Q4
11/8/2023-0.14USD-13.00 MUSD-2023 Q3
8/9/2023-0.14USD-13.47 MUSD-2023 Q2
5/10/2023-0.15USD-11.80 MUSD-2023 Q1
3/15/2023-0.14USD-13.89 MUSD-2022 Q4

EESG©

Eulerpool ESG Scorecard© for the Apyx Medical stock

44/100
16
Environment
34
Social
81
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees52
Percentage of women in management—
Percentage of Asian employees14.2
Share of Asian management—
Percentage of Hispanic/Latino employees15.5
Hispano/Latino Management share—
Percentage of Black employees4.7
Black Management Share—
Percentage of white employees63.5
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Apyx Medical shareholder structure

% Name
9.39184%
Nantahala Capital Management, LLC
Nantahala Capital Management, LLC
9.23270%
Archon Capital Management LLC
Archon Capital Management LLC
8.88643%
Vanderfelt (William Weeks)
Vanderfelt (William Weeks)
6.86428%
Royce Investment Partners
Royce Investment Partners
4.91304%
Vizirgianakis (Stavros G)
Vizirgianakis (Stavros G)
4.15219%
The Vanguard Group, Inc.
The Vanguard Group, Inc.

Apyx Medical Beneficial Ownership Filings (SEC 13D/G)

Free Float
86.0%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
50.20%
Glenn A. Little
Glenn A. Little
SEC ↗
14.40%
RENN CAPITAL GROUP, INC.
RENN CAPITAL GROUP, INC.
SEC ↗
11.00%
William Zolezzi
William Zolezzi
SEC ↗
11.00%
Divisadero Street Partners, L.P.
Divisadero Street Partners, L.P.
SEC ↗
11.00%
Divisadero Street Partners GP, LLC
Divisadero Street Partners GP, LLC
SEC ↗
9.99%
Nantahala Capital Management, LLC
Nantahala Capital Management, LLC
SEC ↗
9.99%
37-1475292
37-1475292
SEC ↗
9.93%
S
S
SEC ↗
9.90%
RTW Investments, LP
RTW Investments, LP
SEC ↗
9.90%
Roderick Wong
Roderick Wong
SEC ↗

Apyx Medical Executives and Management Board

8 members · avg. age 63 · 25 % women

CG

Mr. Charles Goodwin (59)

President, Chief Executive Officer, Director · since 2017

975,971.00 USD

Management

MH

Mr. Matthew Hill (56)

Chief Financial Officer, Treasurer, Secretary

780,234.00 USD
MC

Mr. Moshe Citronowicz (72)

Senior Vice President

483,478.00 USD
SR

Mr. Shawn Roman (54)

Chief Operating Officer

425,594.00 USD

Board of Directors

LW

Mr. Lawrence Waldman (78)

Lead Independent Director

113,331.00 USD
MB

Ms. Minnie Baylor-Henry (77)

Independent Director

65,456.00 USD
WL

Ms. Wendy Levine (52)

Independent Director

53,581.00 USD
SV

Mr. Stavros Vizirgianakis (54)

Independent Chairman of the Board

40,697.00 USD

Frequently asked questions about Apyx Medical

Apyx Medical Corp is a medical technology company focused on developing and commercializing innovative thermal surgical solutions. The company's business model revolves around the development, manufacturing, and sale of advanced energy surgical devices. Apyx Medical Corp's flagship product, J-Plasma®, utilizes a helium plasma technology to provide precise tissue cutting, coagulation, and ablation with reduced thermal spread. This cutting-edge technology is widely used in various surgical specialties, including gynecology, dermatology, and plastic surgery. Apyx Medical Corp aims to provide healthcare professionals with state-of-the-art solutions that enhance patient safety, improve outcomes, and optimize surgical procedures.

Apyx Medical Corp is primarily active in the medical technology industry. As a leading provider of innovative surgical solutions, Apyx Medical Corp focuses on advancing the field of cosmetic and surgical procedures. With their cutting-edge technology and expertise, they cater to a wide range of medical specialties including plastic surgery, dermatology, and gynecology. By offering high-quality products and groundbreaking technologies, Apyx Medical Corp plays a significant role in enhancing patient outcomes and revolutionizing the way surgical procedures are performed.

The main competitors of Apyx Medical Corp in the market include companies such as Medtronic, ConMed Corporation, and Ethicon. These companies also operate in the medical device industry, offering similar products and solutions. Apyx Medical Corp faces competition in areas like electrosurgery systems, advanced energy surgical devices, and cosmetic surgery and dermatology solutions, among others. It is important for investors and stakeholders to be aware of the competitive landscape in order to analyze market dynamics, evaluate company performance, and make informed decisions regarding Apyx Medical Corp.

Apyx Medical Corp, formerly known as Bovie Medical Corporation, is a leading medical technology company that develops and markets innovative energy-based surgical solutions. With a rich history dating back to its founding in 1926, Apyx Medical Corp has continuously evolved to become a global provider of cutting-edge medical devices used in various medical specialties. The company's dedication to research and development has resulted in the creation of advanced products like J-Plasma®, a low-temperature plasma technology used in surgical and aesthetic procedures. Apyx Medical Corp strives to deliver superior medical solutions, improving patient outcomes and advancing the field of healthcare worldwide.

Apyx Medical Corp, a leading medical technology company, has accomplished several significant milestones. The company launched its flagship product, Renuvion, a revolutionary device used for precision surgery in aesthetic and cosmetic procedures. Apyx Medical Corp also expanded its global footprint by securing regulatory approvals in key markets worldwide, including the European Union and Canada. The company's dedication to innovation and excellence led to multiple prestigious awards and recognition, highlighting its position as a market leader. Additionally, Apyx Medical Corp successfully established strategic partnerships with renowned healthcare institutions, fostering collaborative research and development initiatives. With these achievements, Apyx Medical Corp solidifies its reputation as a trailblazer in the medical technology industry.

Apyx Medical Corp is primarily present in the United States.

Apyx Medical Corp represents a set of core values and corporate philosophy that are integral to their mission. The company is committed to delivering innovative energy-based technologies for various surgical specialties, including cosmetic surgery and gynecology. Apyx Medical Corp focuses on providing safe, reliable, and effective solutions to healthcare professionals, ensuring patient satisfaction and well-being. With a dedication to continuous improvement and excellence, Apyx Medical Corp aims to advance medical advancements and elevate patient care standards. By prioritizing quality, innovation, and customer needs, Apyx Medical Corp remains a trusted leader in the medical aesthetics industry.

Analysts currently set an average price target of 5.87 USD for the Apyx Medical stock (median: 5.61 USD), implying +93.6 % versus the latest price. The consensus is based on 11 analyst ratings.

Apyx Medical Analyst Price Targets 2026

11 analysts currently rate the Apyx Medical stock: 9 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Apyx Medical to generate revenue of 59.55 M USD and earnings per share of -0.23 USD.

Apyx Medical Analyst Price Targets 2026

Converted at the current exchange rate, the Apyx Medical share trades at 2.62 EUR (3.03 USD).

The Apyx Medical share (APYX) is listed on 3 stock exchanges, including: NASDAQ (APYX), Frankfurt (BOV.F), München (BOV.MU).

The Apyx Medical Corp is an internationally operating company that specializes in the development and marketing of innovative medical products. Its business model is focused on supporting doctors and medical facilities in improving clinical outcomes while optimizing patient results. The company specializes in three main areas: surgery, dermatology and aesthetics, and veterinary medicine. In surgery, the company offers innovative solutions to support operations. It utilizes ultrasound-based technology to make these processes faster, more precise, and safer. One of its most well-known products is the J-Plasma system, used in plastic surgery operations. This is a surgical instrument that allows doctors to perform precise incisions while minimizing bleeding and scarring. In dermatology and aesthetics, Apyx Medical provides solutions for skin treatment and improving outward appearance. One of its flagship products is the Renuvion J-Plasma handpiece, used in both dermatology and plastic surgery. This handpiece generates a plasma beam that rejuvenates the skin and reduces wrinkles. Additionally, Apyx Medical Corp also offers IPL systems, laser devices, and other tools for treating various skin conditions and removing hair and tattoos. Veterinary medicine is another important sector for the company. Apyx Medical provides solutions to improve animal treatment. The company has extensive experience in developing medical devices and instruments used in the veterinary field. These products are tailored to the needs of veterinarians and clinics, including surgical instruments, laser devices, and other tools for animal treatment. The business model of Apyx Medical Corp is based on the combination of research, development, and sales of innovative medical products. The company emphasizes close collaboration with doctors, clinics, and research institutions to understand customer needs and develop innovative solutions. Patient safety and health are at the forefront of the company's priorities. Apyx Medical Corp has a strong market presence in the United States, Europe, and Asia and aims to offer its customers innovative and high-quality solutions worldwide. The company continuously invests in research and development to expand its portfolio of innovative products and services and provide its customers with the best possible quality. In summary, the business model of Apyx Medical Corp aims to support clinical practice through the development and marketing of innovative medical products. The company offers solutions in three main areas: surgery, dermatology and aesthetics, and veterinary medicine. Close collaboration with customers and investment in research and development are key elements of this business model.

The expected revenue of Apyx Medical is 59.55 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Apyx Medical is -9.53 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Apyx Medical is currently -13.41. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Apyx Medical stock.

The price-to-sales ratio (P/S) of Apyx Medical is currently 2.15. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Apyx Medical stock.

The Eulerpool Quality Score for Apyx Medical is 4/10.

The ISIN of Apyx Medical is US03837C1062. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Apyx Medical is A2PBJC. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Apyx Medical is APYX. The ticker symbol is used to trade Apyx Medical shares on the stock exchange.

Apyx Medical paid dividends every year for the past 0 years.

Apyx Medical is assigned to the 'Health' sector.

The dividends of Apyx Medical are distributed in USD.

All fundamentals and in-depth analysis of Apyx Medical

Our stock analysis for Apyx Medical stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Apyx Medical. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Apyx Medical Stock
Apyx Medical Revenue→
Apyx Medical Stock
Apyx Medical Net Income→
Apyx Medical Stock
Apyx Medical P/E→
Apyx Medical Stock
Apyx Medical P/S→
Apyx Medical Stock
Apyx Medical EBIT→
Apyx Medical Stock
Apyx Medical Dividend→
Apyx Medical Stock
Apyx Medical Directors Dealings→
Apyx Medical Stock
Apyx Medical Stocks→
Apyx Medical Stock
Apyx Medical Market capitalization→
Apyx Medical Stock
Apyx Medical Debt→
Apyx Medical Stock
Apyx Medical Liabilities→
Apyx Medical Stock
Apyx Medical Equity→
Apyx Medical Stock
Apyx Medical AAQS→
Apyx Medical Stock
Apyx Medical Employees→
Apyx Medical Stock
Apyx Medical ROE→
Apyx Medical Stock
Apyx Medical ROA→
Apyx Medical Stock
Apyx Medical ROCE→
Apyx Medical Stock
Apyx Medical News→
Apyx Medical Stock
Apyx Medical Analyst Price Targets→

Health Stocks

AquaBounty TechnologiesAptorum GroupAquestive TherapeuticsAptocromArab Drug Company for Pharmaceuticals and Chemical Industries SAEAptevo TherapeuticsArabian International Healthcare Holding Company SJSCAptamer SciencesArbutus BiopharmaAptamer GroupArch BiopartnersAptahemAll Stocks A–Z →